Onasemnogene abeparvovec commonly linked to hepatotoxicity
27 Feb 2021
Hepatotoxicity is common after treatment with onasemnogene abeparvovec for spinal muscular atrophy, a recent study has found. Clinicians should anticipate and be ready to manage such adverse events, and be aware of any potential underlying conditions that could aggravate them.
Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer
14 Jan 2021;
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.
Manage Account
Change Password
Sign Out
